The congenital heart disease (chd) global market report 2024 from The Business Research Company provides comprehensive market statistics, including global market size, regional shares, competitor market share, detailed segments, trends, and opportunities. This report offers an in-depth analysis of current and future industry scenarios, delivering a complete perspective for thriving in the industrial automation software market.
Congenital Heart Disease (CHD) Market, 2024 report by The Business Research Company offers comprehensive insights into the current state of the market and highlights future growth opportunities.
Market Size –
The congenital heart disease (CHD) market size has grown strongly in recent years. It will grow from $4.03 billion in 2023 to $4.42 billion in 2024 at a compound annual growth rate (CAGR) of 9.7%. The growth in the historic period can be attributed to the increased prevalence of risk factors such as obesity and smoking, improved diagnostic technologies, expanded geriatric population, heightened awareness campaigns, enhanced reimbursement policies, and increased investment in research and development.
The congenital heart disease (CHD) market size is expected to see strong growth in the next few years. It will grow to $6.43 billion in 2028 at a compound annual growth rate (CAGR) of 9.8%. The growth in the forecast period can be attributed to expanding access to healthcare services in developing regions, continuous innovation in cardiac imaging technologies, growing awareness campaigns promoting early detection and treatment, rising healthcare expenditure globally, and the development of personalized medicine. Major trends in the forecast period include adoption of minimally invasive surgical techniques, expanding use of telemedicine for remote patient monitoring and consultations, rising demand for personalized treatment approaches, development of innovative implantable devices with enhanced functionality and longevity, integration of artificial intelligence and machine learning in diagnostic and therapeutic processes.
Order your report now for swift delivery @
https://www.thebusinessresearchcompany.com/report/congenital-heart-disease-chd-global-market-report
Scope Of Congenital Heart Disease (CHD) Market
The Business Research Company’s reports encompass a wide range of information, including:
1. Market Size (Historic and Forecast): Analysis of the market’s historical performance and projections for future growth.
2. Drivers: Examination of the key factors propelling market growth.
3. Trends: Identification of emerging trends and patterns shaping the market landscape.
4. Key Segments: Breakdown of the market into its primary segments and their respective performance.
5. Focus Regions and Geographies: Insight into the most critical regions and geographical areas influencing the market.
6. Macro Economic Factors: Assessment of broader economic elements impacting the market.
Congenital Heart Disease (CHD) Market Overview
Market Drivers –
The increase in maternal diabetes cases is expected to propel the growth of the congenital heart disease (CHD) market going forward. Maternal diabetes, or gestational diabetes mellitus (GDM), refers to diabetes that arises during pregnancy in women who did not have diabetes before conception. Maternal diabetes is caused by changes in lifestyle, including sedentary behavior and unhealthy dietary habits, and an overall rise in obesity rates among women of childbearing age. Maternal diabetes can lead to congenital heart disease (CHD) in infants due to the high blood sugar levels affecting fetal heart development. The elevated glucose levels in the mother’s blood can disrupt the normal development of the baby’s heart, increasing the risk of CHD. For instance, in January 2023, according to the Centers for Disease Control and Prevention, a US-based government agency for public health, the percentage of pregnant mothers diagnosed with gestational diabetes had risen to 8.3% in 2021 from 6.0% in the previous five years. Therefore, the increase in maternal diabetes cases is driving the growth of the congenital heart disease (CHD) market.
Market Trends –
Major companies operating in the congenital heart disease market are developing non-surgical heart valves to improve patient outcomes and quality of life. Non-surgical heart valves, or transcatheters, are medical devices that treat heart valve diseases without needing traditional open-heart surgery. For instance, in February 2023, Medtronic, a US-based medical technology company, reintroduced its Harmony Transcatheter Pulmonary Valve (TPV) System. It is a groundbreaking, minimally invasive alternative to open-heart surgery for patients with congenital heart disease, specifically those with native or surgically repaired right ventricular outflow tract (RVOT) anomalies. This system is the first FDA-approved valve designed for the right side, providing a non-surgical solution for patients with severe pulmonary valve regurgitation. The Harmony TPV System received U.S. FDA approval in 2021. It was reintroduced following a voluntary recall, demonstrating Medtronic’s commitment to advancing solutions for congenital heart disease patients.
The congenital heart disease (CHD) market covered in this report is segmented –
1) By Type: Heart Valve Defects, Heart Wall Defects, Blood Vessel Defects, Other Types
2) By Diagnosis: Electrocardiogram, Chest X-ray, Echocardiogram, Transesophageal Echocardiogram, Pulse Oximetry, Exercise Stress Test, Cardiac Computed Tomography (CT) Scan Or Magnetic Resonance Imaging (MRI), Cardiac Catheterization, Other Diagnosis
3) By Treatment: Interventional Cardiology, Cardiac Surgery, Telemedicine, Medication Management, Lifestyle Modifications
4) By Age Group: Infants, Children, Adolescents, Adults
5) By Application: Hospitals And Clinics, Diagnostic Centers, Ambulatory Surgical Centers, Research And Academic Institutions
Get an inside scoop of the congenital heart disease (chd) market, Request now for Sample Report @
https://www.thebusinessresearchcompany.com/sample.aspx?id=15545&type=smp
Regional Insights –
North America was the largest region in the congenital heart disease (CHD) market in 2023. The regions covered in the congenital heart disease (CHD) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Key Companies –
Major companies operating in the congenital heart disease (CHD) market are Pfizer Inc., AstraZeneca Plc, Abbott Laboratories, Novartis AG, Medtronic, Siemens Healthineers, Philips Healthcare, Roche Diagnostics International Ltd., Boston Scientific Corp., Laboratory Corporation of America Holdings (LabCorp), Terumo Corporation, Mindray Medical International Limited, Canon Medical Systems Corporation, Masimo Corporation, Neusoft Corp., Carestream Health, Midmark Corporation, Contec Medical Systems, Randox Laboratories Ltd., Schiller AG, BPL Medical Technologies, Compumedics Limited, Biocare Medical, Bionet America Inc., Nasan Medical Electronics Pvt Ltd
Table of Contents
1. Executive Summary
2. Congenital Heart Disease (CHD) Market Report Structure
3. Congenital Heart Disease (CHD) Market Trends And Strategies
4. Congenital Heart Disease (CHD) Market – Macro Economic Scenario
5. Congenital Heart Disease (CHD) Market Size And Growth
…..
27. Congenital Heart Disease (CHD) Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
